Patent EP0011609A2 successfully refreshed from Google Patents.
EP0011609A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Xanthine derivatives and pharmaceutical preparations containing these derivatives for use in the treatment of chronic obstructive airway disease and cardiac disease
Assignee: Draco AB
•
Filing: 1979-09-28
•
Granted: —
•
Expires: 1999-09-28
Abstract
Abstract A method for the treatment of chronic obstructive airway disease or cardiac disease, characterized by the administration of a compound of the formulawherein R is n-propyl, n-butyl or isobutyl or a therapeutically acceptable salt thereof.
Inventors
- 👤 Per Gunnar Kjellin
- 👤 Carl Göran August Persson
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-07 12:55
CPC Classifications
C; C07; C07D; C07D239/00; C07D239/02; C07D239/24; C07D239/28; C07D239/46; C07D239/52; C07D239/54; C07D239/545; A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61K31/519; A61K31/52; A61P; A61P11/00; A61P11/08; A61P9/00; C07D473/00; C07D473/02; C07D473/04; C07D473/06
Claims Analysis
Total Claims: 3
Claim 1
Independent Claim
38 words
or a therapeutically acceptable salt thereof, wherein R is -CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH 3 or -CH 2 CH(CH 3 ) 2 in association with a pharmaceutically acceptable carrier.
Claim 2
Dependent Claim
60 words
A pharmaceutical preparation for the treatment of cardiac disease comprising as active ingredient an effective amount of a compound of the formula or a therapeutically acceptable salt thereof, wherein R is -CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH 3 or -CH 2 CH(CH 3 ) 2 in association with a pharmaceutically acceptable carrier.
Claim 3
Dependent Claim
27 words
A compound useful as an intermediate for the preparation of therapeutically active xanthine derivatives, which intermediate is characterized by the formula wherein R is n-propyl and n-butyl.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.